Immunitybio inc (IBRX) - News Archive

ImmunityBio Reports Significant Growth in Q2 2025: Revenue Surges by 60% Amid Competitive Landscape CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a prominent player in the immunotherapy landscape, has revealed a...

In an important development for the treatment of bladder cancer, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization to ImmunityBio, Inc. for its groundbreaking product,...

ImmunityBio Advances Immunotherapy Landscape: Key Opinion Leader Meeting and Regulatory Milestones in 2025 Culver City, California - ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering company in the field of immunotherapy,...

ImmunityBio, Inc. a prominent player in the field of immunotherapy, has recently achieved key designations and made substantial advancements that may reshape treatment paradigms for patients suffering from pancreatic ca...

ImmunityBio s Progress in FDA Submissions Amid Market Challenges In a significant development for the oncology sector, ImmunityBio, Inc. (NASDAQ: IBRX) has announced its forward momentum in discussions with the U.S. Foo...

Recently, ImmunityBio, Inc. has announced the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for its innovative immunotherapy, ANKTIVA (nogapendekin alfa inbakicept-pmln). Effective J...

Culver City, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering company in the field of immunotherapy, has successfully completed the post-approval enrollment of the 100th patient in its ANKTIVAs clinical trial targe...

Culver City, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), a pioneering force in immunotherapy, has announced promising results from its QUILT 3.055 trial demonstrating robust long-term survival benefits for patients sufferi...

CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX) has made a significant leap in the accessibility of its cancer treatment, ANKTIVA (nogapendekin alfa inbakicept-pmln), securing coverage from more than a dozen insura...

A Groundbreaking Immunotherapy Trial to Combat Endometrial Cancer: ImmunityBio s Innovative ApproachIn a significant stride toward potentially transforming the treatment landscape for endometrial cancer, ImmunityBio, In...

ImmunityBio, a biopharmaceutical company, has made significant progress in the field of immunotherapy with the administration of ANKTIVA (nogapendekin alfa inbakicept-pmln) to multiple patients in the United States. Thi...

Intro: ImmunityBio, a biotechnology company known for its groundbreaking research in cancer immunotherapy, recently made significant announcements regarding its upcoming Annual Meeting of Stockholders and advancements i...

Biopharmaceutical company ImmunityBio, Inc. (NASDAQ: IBRX) has recently announced that its 2024 Annual Meeting of Stockholders will take place on June 11, 2024, at 9:30 a.m. Pacific Time. The meeting will be conducted i...

CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX) has made significant strides in the arena of bladder cancer treatment. Highlighting these breakthroughs, a series of three enlightening podcasts were recently publish...

In a recent series of podcasts conducted by UroToday, ImmunityBio, Inc. reveals groundbreaking developments in the field of bladder cancer research and the FDA approval of their novel therapy, ANKTIVA, for the treatment...

U.S.-based immunotherapy company, ImmunityBio Inc. (NASDAQ: IBRX), recently confirmed that it has successfully completed manufacturing the Drug Substance (DS), a key component required for creating its biotherapeutic dr...

ImmunityBio, a leading biotechnology company based in Culver City, California, has recently inked an exclusive global arrangement with the esteemed Serum Institute of India. This groundbreaking partnership aims to revol...

In a ground-breaking announcement that marked a new chapter in cancer therapy, ImmunityBio unveiled news of the FDA s recent approval of ANKTIVA (nogapendekin alfa inbakicept-pmln). The historic announcement was made by...

In a recent announcement, ImmunityBio, a leading immunotherapy company, shared positive overall survival outcomes from the QUILT 3.055 study. The study evaluated the effectiveness of ANKTIVA (N-803) in combination with...

ImmunityBio, Inc., a leading immunotherapy company, has achieved a significant milestone in the field of cancer treatment. The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA (N-803) in combinat...